84 - Commonalities and Differences in Antimicrobial Treatment of Resistant Pathogens

Thursday, October 17, 2024

3:15 PM – 4:30 PM US PT

Location: Concourse 152

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA

Field Medical Officer
Centers for Disease Control & Prevention & Einstein/ Montefiore
New York, NY, United States
Yohei Doi, MD, PHD (he/him/his)

Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh
Toyoake, Aichi, Japan

Faculty(s)

Katsunori Yanagihara, MD, PhD

Professor
Nagasaki University
Nagasaki, Nagasaki, Japan
KH

Kayoko Hayakawa, Md, PhD

Chief Physician
Disease Control and Prevention Center
National Center for Global Health and Medicine
Shinjuku, Tokyo, Japan
Payal Patel, MD, MPH, FIDSA (she/her/hers)

System Wide Director of Antimicrobial Stewardship
Intermountain Healthcare
Salt Lake City, UT, United States

Disclosure(s):

Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA: No financial relationships to disclose

Yohei Doi, MD, PHD: AbbVie: Advisor/Consultant (Terminated, October 31, 2023); bioMerieux: Advisor/Consultant (Terminated, December 31, 2022); Entasis Pharmaceuticals: Grant/Research Support (Ongoing); FujiFilm: Advisor/Consultant (Terminated, December 31, 2022); Gilead: Advisor/Consultant (Terminated, November 30, 2023), Honoraria (Terminated, November 30, 2023); GlaxoSmithKline (GSK): Advisor/Consultant (Terminated, March 31, 2023); Meiji Seika Pharma: Advisor/Consultant (Ongoing); Moderna: Advisor/Consultant (Terminated, November 30, 2023); MSD: Advisor/Consultant (Terminated, December 31, 2022), Honoraria (Terminated, December 31, 2022); Pfizer, Inc.: Advisor/Consultant (Terminated, November 30, 2023); Shionogi: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing)

Katsunori Yanagihara, MD, PhD: Abbott Diagnostics: Honoraria (Ongoing); Becton, Dickinson and Company (BD): Honoraria (Ongoing); bioMerieux Inc.: Honoraria (Ongoing); Glaxo Smith Kline: Honoraria (Ongoing); Meiji Seika Pharma Co., Ltd.: Grant/Research Support (Ongoing), Honoraria (Ongoing); Pfizer, Inc.: Honoraria (Ongoing); Roche Diagnostics: Honoraria (Ongoing); Shionogi & Co.,Ltd.: Grant/Research Support (Ongoing), Honoraria (Ongoing)

Kayoko Hayakawa, Md, PhD: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the differences in local epidemiology of antimicrobial resistance in north america vs. east asia;
explain how epidemiological differences in resistance relate to differences in treatment guidelines;
explain how ongoing changes in resistance patterns necessitate ongoing evaluation of treatment guidelines.

Presentations:

3:15 PM – 3:40 PM US PT

Epidemiology of Antimicrobial-Resistant Infections in North America and East Asia
Speaker: Katsunori Yanagihara, MD, PhD – Nagasaki University
3:40 PM – 4:05 PM US PT

Antimicrobial Treatment Guidelines and their Rationale in Japan
Speaker: Kayoko Hayakawa, Md, PhD – National Center for Global Health and Medicine
4:05 PM – 4:30 PM US PT

This is How we Do It: US Approach to Antimicrobial Stewardship Guidelines
Speaker: Payal K. Patel, MD, MPH, FIDSA (she/her/hers) – Intermountain Healthcare